

# ZEVENBERGEN GENE FUND

## FACT SHEET - 2QTR25

### INVESTMENT STYLE

- **Investment Approach**
  - Long-term perspective, invest with “business owner” disposition
  - Founder-led, visionary management teams prioritizing growth over profits
- **High-Conviction Portfolio Construction**
  - Concentrated positions
  - Long-term holding periods
- **Independent, Bottom-Up Research**
  - Essential to understanding fundamental growth prospects and valuation

### QUESTIONS?

Please Contact

Bill Cook  
833.844.5457  
cook@zci.com

### EVOLUTION OF COMPANY GROWTH



### FUND INFORMATION

Ticker	ZVGNX	ZVGIX
Share Class	Investor	Institutional
Net Expense Ratio*	1.30%	1.00%
*Shareholders pay net expense ratio. ZCI has contractually agreed to keep fund expenses at or below the net expense ratio through 10/31/2025.		
Gross Expense Ratio	1.62%	1.32%
Strategy Inception	1994	
Fund Inception	August 31, 2015	

### TOP HOLDINGS AS OF 06/30/25

	% of NAV
NVIDIA Corporation	9.5%
Axon Enterprise, Inc.	8.4%
Tesla, Inc.	8.1%
MercadoLibre, Inc.	7.9%
Shopify Inc.	7.1%
Netflix, Inc.	5.0%
The Trade Desk, Inc.	4.7%
Amazon.com, Inc.	4.6%
Snowflake Inc.	4.4%
Spotify Technology S.A.	4.3%
	64.0%



### 2-STAR OVERALL MORNINGSTAR RATING™

Rating is based on risk adjusted total return for Investor Shares and Institutional Shares out of 1,033 Funds in the Large Growth Category as of June 30, 2025. The overall rating is derived from the three- and five-year average annual returns.

### INVESTMENT PERFORMANCE


As of: 06/30/2025	QUARTER TO DATE	YEAR TO DATE	ONE YEAR	THREE YEAR Annualized	FIVE YEAR Annualized	SINCE INCEPTION (08/31/15) Annualized
<b>ZVGNX</b> (Investor Share Class)	35.10%	14.71%	41.61%	34.22%	11.12%	19.29%
<b>ZVGIX</b> (Institutional Share Class)	35.20%	14.90%	42.05%	34.63%	11.46%	19.62%
<b>RUSSELL 3000® GROWTH</b>	17.72%	5.89%	16.99%	25.11%	17.57%	17.09%

Performance data quoted represents past performance; past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. The Fund imposes a 1.00% redemption fee on shares held for 90 days or less. Performance data does not reflect the redemption fee. If it had, return would be reduced. Current performance of the fund may be lower or higher than the performance quote. Performance data current to the most recent month end may be obtained by calling 1.844.986.2746.


# ZEVENBERGEN GENEAL FUND

## FACT SHEET - 2QTR25

### MARKET SECTORS



### MARKET CAPITALIZATION



### FUND CHARACTERISTICS

	GENEA FUND	RUSSELL 3000® GROWTH
Number of Holdings:	27	1,485
Sales/Share Growth - 1 Year:	19.1%	13.7%
L.T. Growth Forecast IBES Medians:	21.3%	17.9%
Portfolio P/E (IBES 1 Yr Forecast EPS):	59.1X	31.6X
PEG Ratio (L.T. Growth Forecast-IBES Medians):	2.8X	1.8X
Price/Sales:	9.0X	6.5X
Wtd. Average Market Cap. (\$ Billions):	\$650.0	\$1,676.7

Earnings growth is not a measure of the Fund's future performance

As of 06/30/2025

Fund holdings and sector allocations are subject to change and should not be considered a recommendation to buy or sell any security.

Sector Weightings, Market Capitalization, Portfolio Characteristics Source: The Bank of New York Mellon Corporation.

Market Capitalization Ranges (\$ Billions): Large = \$194.77 & above; Medium/Large = \$54.39-194.77; Medium = \$15.84-54.39; Medium/Small = \$5.15-15.84; Small = \$5.15 & below.

All performance-related statistics presented do not represent actual performance and are gross of all fees and expenses that an investor would have paid, except where specifically noted. To understand the overall impact of fees, please review the composite performance returns provided.

Sales/Share Growth - 1 Year: the latest reported fiscal year gross revenues divided by one-year-ago fiscal year gross revenues.

Long Term Growth Forecast: indicates the consensus outlook for earnings-per-share growth. I/B/E/S provides medians of research analysts' estimates for companies long-term (typically five years) growth rates.

Portfolio Price/Earnings: the ratio of a firm's closing stock price & its one year forecasted earnings-per-share.

Price/Earnings to Growth Ratio: the price-to-earnings ratio divided by the growth rate of earnings.

Price/Sales: the ratio of each company's price and the previous 12-months revenues.

Weighted Average Market Cap: each stock's market capitalization and its weight in the portfolio are used to determine the portfolio's average.

Russell 3000® Growth: this index measures the performance of those Russell 3000 companies with higher price-to-book ratios and higher forecasted growth values. One cannot invest directly in an index. Russell Indices are trademarks of the London Stock Exchange Group. Source data provided by the London Stock Exchange Group.

© 2025 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history, without adjustment for sales loads. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating™ for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating™ metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Zevenbergen Genea Fund was rated against the following numbers of Large Growth Funds over the following time periods: 1,033 funds in the last three years and 954 funds in the last five years. With respect to these Large Growth Funds, Zevenbergen Genea Fund received a Morningstar Rating of 4 stars for the three-year period and 1 star for the five-year period.

**Past Performance is no guarantee of future results.**

The fund's investment objectives, risks, charges and expenses must be considered carefully before investing. The statutory and summary prospectus contain this and other important information about the investment company, and may be obtained by calling 1.844.986.2746, or visiting [www.zci.com/funds](http://www.zci.com/funds). Read carefully before investing.

Mutual fund investing involves risk, including the loss of principal. The Funds invest in foreign securities which involve greater volatility and political, economic and currency risks and differences in accounting methods. Non-diversified funds may hold a significant percentage of their assets in the securities of fewer companies and therefore events affecting those companies have a greater impact on the funds than on a diversified fund. If the Funds invest in a few sectors they may have increased exposure to price movements of those sectors. Small and medium capitalization companies tend to have limited liquidity and greater price volatility than large capitalization companies.

Zevenbergen Capital Investments LLC (ZCI) is the investment adviser of the Zevenbergen Funds which are distributed by Quasar Distributors, LLC.